好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

2024 Annual Meeting | Industry Therapeutic Update from Genentech: Moving Upstream: The Role of Interleukin-6 in MOGAD and Autoimmune Encephalitis

Sunday 04/14/24
11:45 AM - 12:45 PM MDT Add To Calendar
This program will be presented both in-person and online
This program is not expected to be available in the meeting's On Demand product.
Industry Therapeutic Update
Ivana Vodopivec, MD
General Neurology, Autoimmune Neurology
This Industry Therapeutic Update (ITU) explores unmet needs, diagnosis, and the evolving therapeutic landscape across a spectrum of autoantibody-driven autoimmune disorders, with a focus on myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and autoimmune encephalitis (AE). Additionally, the session discusses perspectives on the diseases' pathophysiology including the potential role of interleukin-6 (IL-6) signalling.
This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2024 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.
No CME available

Program Evaluations

Event Timeline
11:45 AM - 12:45 PM MDT Speaker Industry Therapeutic Update from Genentech: Moving Upstream: The Role of Interleukin-6 in MOGAD and Autoimmune Encephalitis
Faculty Disclosures
Ivana Vodopivec, MD Dr. Vodopivec has received personal compensation for serving as an employee of Roche. An immediate family member of Dr. Vodopivec has received personal compensation for serving as an employee of Novartis. Dr. Vodopivec has stock in Roche.